FDG; Imaging; MTV; Myeloma; PET; Radiology, Nuclear Medicine and Imaging
Abstract :
[en] [en] BACKGROUND: 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) positron emission tomography combined with low-dose computed tomography (PET/CT) can be used at diagnosis to identify myeloma-defining events and also provides prognostic factors. The aim of this study was to assess the prognostic significance of baseline [18F]FDG PET/CT visual IMPeTUs (Italian myeloma criteria for PET Use)-based parameters and/or total metabolic tumor volume (TMTV) in a single-center population of patients with newly diagnosed multiple myeloma (NDMM) eligible for transplantation.
METHODS: Patients with MM who underwent a baseline [18F]FDG PET/CT were retrospectively selected from a large internal database of the University Hospital of Liege (Liege, Belgium). Initially, all PET/CT images were visually analyzed using IMPeTUs criteria, followed by delineation of TMTV using a semi-automatic lesion delineation workflow, including [18F]FDG-positive MM focal lesions (FL) with an absolute SUV threshold set at 4.0. In a first step, to ensure PET/CT scans accurate reporting, the agreement between two nuclear medicine physicians with distinct experience was assessed. In the second step, univariable and multivariable analyses were conducted to determine the prognostic significance of [18F]FDG PET/CT parameters on progression free survival (PFS) and overall survival (OS), respectively.
RESULTS: A total of 40 patients with NDMM were included in the study. The observers agreement in the analysis [18F]FDG PET/CT images was substantial for the presence of spine FL, extra spine FL, at least one fracture and paramedullary disease (Cohen's kappa 0.79, 0.87, 0.75 and 0.64, respectively). For the presence of skull FL and extramedullary disease the agreement was moderate (Cohen's kappa 0.56 and 0.53, respectively). Among [18F]FDG PET/CT parameters, a high number of delineated volumes of interest (VOI) using the SUV4.0 threshold was the only independent prognostic factor associated with PFS [HR (95% CI): 1.03 (1.004-1.05), P = 0.019] while a high number of FL (n > 10; F group 4) was the only independent prognostic factor associated with OS [HR (95% CI): 19.10 (1.90-191.95), P = 0.01].
CONCLUSION: Our work confirms the reproducibility IMPeTUs criteria. Furthermore, it demonstrates that a high number of FL (n > 10; IMPeTUs F group 4), reflecting a high [18F]FDG-avid tumor burden, is an independent prognostic factor for OS. The prognostic value of the TMTV delineated using a SUV4.0 threshold was not significant. Nevertheless, the count of delineated [18F]FDG-avid lesions VOI using a SUV4.0 threshold was an independent prognostic factor for PFS.
Disciplines :
Radiology, nuclear medicine & imaging
Author, co-author :
MARCHIORI, Silvano ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de médecine nucléaire et imagerie onco
Cousin, François ; Université de Liège - ULiège > Département des sciences cliniques
Papadopoulos, Iraklis ; Université de Liège - ULiège > Santé publique : de la Biostatistique à la Promotion de la Santé
Bernard, Claire ; Université de Liège - ULiège > Département de physique
THYS, Marie ; Centre Hospitalier Universitaire de Liège - CHU > > Service des informations médico économiques (SIME)
DE PRIJCK, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'hématologie clinique
Pirotte, Michelle ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'hématologie clinique
Donneau, Anne-Françoise ; Université de Liège - ULiège > Département des sciences de la santé publique
Hustinx, Roland ; Université de Liège - ULiège > Département des sciences cliniques > Médecine nucléaire
Caers, Jo ; Université de Liège - ULiège > Département des sciences cliniques > Hématologie
Withofs, Nadia ; Université de Liège - ULiège > Département des sciences cliniques
Language :
English
Title :
Prognostic value of visual IMPeTUs criteria and metabolic tumor burden at baseline [18F]FDG PET/CT in patients with newly diagnosed multiple myeloma.
Publication date :
28 May 2024
Journal title :
EJNMMI Research
eISSN :
2191-219X
Publisher :
Springer Science and Business Media Deutschland GmbH, Germany
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
H. Ludwig S. Novis Durie A. Meckl A. Hinke B. Durie Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment Oncologist 2020 25 9 e1406 e1413 32335971 7485361 10.1634/theoncologist.2020-0141
N. van de Donk C. Pawlyn K.L. Yong Multiple myeloma Lancet 2021 397 10272 410 427 33516340 10.1016/S0140-6736(21)00135-5
P. Tacchetti L. Pantani F. Patriarca M.T. Petrucci E. Zamagni L. Dozza et al. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study Lancet Haematol 2020 7 12 e861 e873 33242443 10.1016/S2352-3026(20)30323-9
M.V. Mateos M. Cavo J. Blade M.A. Dimopoulos K. Suzuki A. Jakubowiak et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial Lancet 2020 395 10218 132 141 1:CAS:528:DC%2BC1MXitlKhtb%2FI 31836199 10.1016/S0140-6736(19)32956-3
A. Palumbo H. Avet-Loiseau S. Oliva H.M. Lokhorst H. Goldschmidt L. Rosinol et al. Revised international staging system for multiple myeloma: a report from international myeloma working group J Clin Oncol 2015 33 26 2863 2869 1:CAS:528:DC%2BC28XhtVSmsbnE 26240224 4846284 10.1200/JCO.2015.61.2267
M. D'Agostino D.A. Cairns J.J. Lahuerta R. Wester U. Bertsch A. Waage et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European myeloma network (EMN) report within the harmony project J Clin Oncol 2022 40 29 3406 3418 1:CAS:528:DC%2BB38XisFKnsbzN 35605179 10.1200/JCO.21.02614
S. Kumar B. Paiva K.C. Anderson B. Durie O. Landgren P. Moreau et al. International Myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma Lancet Oncol 2016 17 8 e328 e346 27511158 10.1016/S1470-2045(16)30206-6
S.V. Rajkumar M.A. Dimopoulos A. Palumbo J. Blade G. Merlini M.V. Mateos et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma Lancet Oncol 2014 15 12 e538 e548 25439696 10.1016/S1470-2045(14)70442-5
M. Cavo E. Terpos C. Nanni P. Moreau S. Lentzsch S. Zweegman et al. Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group Lancet Oncol 2017 18 4 e206 e217 28368259 10.1016/S1470-2045(17)30189-4
J. Hillengass S. Usmani S.V. Rajkumar B.G.M. Durie M.V. Mateos S. Lonial et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders Lancet Oncol 2019 20 6 e302 e312 31162104 10.1016/S1470-2045(19)30309-2
L. Rasche S.S. Chavan O.W. Stephens P.H. Patel R. Tytarenko C. Ashby et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing Nat Commun 2017 8 1 268 1:STN:280:DC%2BC1cfptValug%3D%3D 28814763 5559527 10.1038/s41467-017-00296-y
E. Zamagni F. Patriarca C. Nanni B. Zannetti E. Englaro A. Pezzi et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation Blood 2011 118 23 5989 5995 1:CAS:528:DC%2BC3MXhs1ansbzI 21900189 10.1182/blood-2011-06-361386
J. Li X. Zhang C. Qin X. Sun X. Xu G. Cao et al. A prognostication system based on clinical parameters and [(18)F]-FDG PET/CT in patients with newly diagnosed multiple myeloma Eur J Nucl Med Mol Imaging 2023 50 6 1665 1670 1:CAS:528:DC%2BB3sXkslentA%3D%3D 36576511 10.1007/s00259-022-06088-x
F. Kraeber-Bodere S. Zweegman A. Perrot C. Hulin D. Caillot T. Facon et al. Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study Haematologica 2023 108 2 621 626 36263839 10.3324/haematol.2021.280051
C. Sachpekidis M. Merz M.S. Raab U. Bertsch V. Weru A. Kopp-Schneider et al. The prognostic significance of [(18)F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs) EJNMMI Res 2021 11 1 100 1:CAS:528:DC%2BB38XksVSktb4%3D 34628525 8502185 10.1186/s13550-021-00846-y
C. Nanni E. Zamagni A. Versari S. Chauvie A. Bianchi M. Rensi et al. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel IMPeTUs (Italian Myeloma criteria for PET USe) Eur J Nucl Med Mol Imaging 2016 43 3 414 421 1:CAS:528:DC%2BC2MXhslWku7zP 26475305 10.1007/s00259-015-3200-9
C. Nanni A. Versari S. Chauvie E. Bertone A. Bianchi M. Rensi et al. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results IMPeTUs (Italian myeloma criteria for PET USe) Eur J Nucl Med Mol Imaging 2018 45 5 712 719 29270787 10.1007/s00259-017-3909-8
S. Deng B. Zhang Y. Zhou X. Xu J. Li S. Sang et al. The role of (18)F-FDG PET/CT in multiple myeloma staging according to IMPeTUs: comparison of the durie-salmon plus and other staging systems Contrast Media Mol Imaging 2018 2018 4198673 30154686 6091330 10.1155/2018/4198673
C. Sachpekidis O. Enqvist J. Ulen A. Kopp-Schneider L. Pan E.K. Mai et al. Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [(18)F]FDG PET/CT predicts survival in multiple myeloma Eur J Nucl Med Mol Imaging 2024 10.1007/s00259-024-06668-z 38456971
J.B. Alberge F. Kraeber-Bodere B. Jamet C. Touzeau H. Caillon S. Wuilleme et al. Molecular signature of (18)F-FDG PET biomarkers in newly diagnosed multiple myeloma patients: a genome-wide transcriptome analysis from the CASSIOPET study J Nucl Med 2022 63 7 1008 1013 1:CAS:528:DC%2BB38XisFShtLjP 35086897 9258580 10.2967/jnumed.121.262884
R. Fonti M. Larobina S. Del Vecchio S. De Luca R. Fabbricini L. Catalano et al. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma J Nucl Med 2012 53 12 1829 1835 1:CAS:528:DC%2BC3sXktFKktw%3D%3D 23071351 10.2967/jnumed.112.106500
J.E. McDonald M.M. Kessler M.W. Gardner A.F. Buros J.A. Ntambi S. Waheed et al. Assessment of total lesion glycolysis by (18)F FDG PET/CT significantly improves prognostic value of GEP and ISS in myeloma Clin Cancer Res 2017 23 8 1981 1987 1:CAS:528:DC%2BC2sXlvFOqtr8%3D 27698001 10.1158/1078-0432.CCR-16-0235
T. Terao Y. Machida T. Tsushima D. Miura K. Narita A. Kitadate et al. Pre-treatment metabolic tumour volume and total lesion glycolysis are superior to conventional positron-emission tomography/computed tomography variables for outcome prediction in patients with newly diagnosed multiple myeloma in clinical practice Br J Haematol 2020 191 2 223 230 1:CAS:528:DC%2BB3cXitFams7jL 32253760 10.1111/bjh.16633
R. Fonti S. Pellegrino L. Catalano F. Pane S. Del Vecchio L. Pace Visual and volumetric parameters by 18F-FDG-PET/CT: a head to head comparison for the prediction of outcome in patients with multiple myeloma Ann Hematol 2020 99 1 127 135 1:CAS:528:DC%2BC1MXitlKiu7bO 31776725 10.1007/s00277-019-03852-2
B. Wan S. Zhang P. Wang P. Deng W. Dai Prognostic value of semi-quantitative parameters of (18)F-FDG PET/CT in newly diagnosed multiple myeloma patients Ann Nucl Med 2023 37 3 155 165 1:CAS:528:DC%2BB38Xjt1Snsr3M 36528697 10.1007/s12149-022-01812-x
H. Lee S.H. Hyun Y.S. Cho S.H. Moon J.Y. Choi K. Kim et al. Cluster analysis of autoencoder-extracted FDG PET/CT features identifies multiple myeloma patients with poor prognosis Sci Rep 2023 13 1 7881 1:CAS:528:DC%2BB3sXhtVGit7nJ 37188831 10185699 10.1038/s41598-023-34653-3
T. Terao Y. Machida K. Narita A. Kuzume R. Tabata T. Tsushima et al. Total diffusion volume in MRI vs. total lesion glycolysis in PET/CT for tumor volume evaluation of multiple myeloma Eur Radiol 2021 31 8 6136 6144 1:CAS:528:DC%2BB3MXmsFGisrs%3D 33496828 10.1007/s00330-021-07687-2
B. Jamet L. Morvan C. Nanni A.V. Michaud C. Bailly S. Chauvie et al. Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials Eur J Nucl Med Mol Imaging 2021 48 4 1005 1015 1:CAS:528:DC%2BB3cXitVGqs7jK 33006656 10.1007/s00259-020-05049-6
I. Khodarahmi H. Alizai M. Chalian E.F. Alaia C.J. Burke S.E. Slasky et al. Imaging spectrum of calvarial abnormalities Radiographics 2021 41 4 1144 1163 34197249 10.1148/rg.2021200198
J. Caers N. Withofs J. Hillengass P. Simoni E. Zamagni R. Hustinx et al. The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma Haematologica 2014 99 4 629 637 24688111 3971072 10.3324/haematol.2013.091918
E. Zamagni C. Nanni L. Dozza T. Carlier C. Bailly P. Tacchetti et al. Standardization of (18)F-FDG-PET/CT according to deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma J Clin Oncol 2021 39 2 116 125 1:CAS:528:DC%2BB38Xhslamurg%3D 33151787 10.1200/JCO.20.00386
L. Rasche C. Schinke F. Maura M.A. Bauer C. Ashby S. Deshpande et al. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states Nat Commun 2022 13 1 4517 1:CAS:528:DC%2BB38XitFWmurzI 35922426 9349320 10.1038/s41467-022-32145-y
S.V. Rajkumar Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management Am J Hematol 2016 91 7 719 734 1:CAS:528:DC%2BC28XpsFGqsLw%3D 27291302 5291298 10.1002/ajh.24402
P. Moreau M. Attal D. Caillot M. Macro L. Karlin L. Garderet et al. Prospective evaluation of magnetic resonance imaging and [(18)F]Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 Trial: results of the IMAJEM study J Clin Oncol 2017 35 25 2911 2918 1:CAS:528:DC%2BC1cXitVemtrzM 28686535 5578392 10.1200/JCO.2017.72.2975
A.V. Michaud-Robert E. Zamagni T. Carlier C. Bailly B. Jamet C. Touzeau et al. Glucose metabolism quantified by SUVmax on baseline FDG-PET/CT predicts survival in newly diagnosed multiple myeloma patients: combined harmonized analysis of two prospective phase III trials Cancers (Basel) 2020 12 9 2532 1:CAS:528:DC%2BB3cXisFKnt7%2FF 32899991 10.3390/cancers12092532
M.I. Morales-Lozano O. Viering S. Samnick P. Rodriguez-Otero A.K. Buck M. Marcos-Jubilar et al. (18)F-FDG and (11)C-Methionine PET/CT in newly diagnosed multiple myeloma patients: comparison of volume-based PET biomarkers Cancers (Basel). 2020 12 4 1042 1:CAS:528:DC%2BB3cXisVCrtb3I 32340251 7226577 10.3390/cancers12041042
S.F. Barrington B. Zwezerijnen H.C.W. de Vet M.W. Heymans N.G. Mikhaeel C.N. Burggraaff et al. Automated segmentation of baseline metabolic total tumor burden in diffuse large B-cell lymphoma: which method is most successful? A study on behalf of the PETRA consortium J Nucl Med 2021 62 3 332 337 1:CAS:528:DC%2BB3MXntlaiu74%3D 32680929 8049348 10.2967/jnumed.119.238923
L. Rasche D. Alapat M. Kumar G. Gershner J. McDonald C.P. Wardell et al. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma Leukemia 2019 33 7 1713 1722 1:STN:280:DC%2BB3cnksVensw%3D%3D 30573775 10.1038/s41375-018-0329-0
T. Terao Y. Machida K. Hirata A. Kuzume R. Tabata T. Tsushima et al. Prognostic impact of metabolic heterogeneity in patients with newly diagnosed multiple myeloma using 18F-FDG PET/CT Clin Nucl Med 2021 46 10 790 796 34172600 10.1097/RLU.0000000000003773
C. Sachpekidis O. Enqvist J. Ulen A. Kopp-Schneider L. Pan A. Jauch et al. Application of an artificial intelligence-based tool in [(18)F]FDG PET/CT for the assessment of bone marrow involvement in multiple myeloma Eur J Nucl Med Mol Imaging 2023 50 12 3697 3708 1:CAS:528:DC%2BB3sXhsFCqu7nI 37493665 10547616 10.1007/s00259-023-06339-5
M.E.S. Takahashi C. Mosci E.M. Souza S.Q. Brunetto E. Etchebehere A.O. Santos et al. Proposal for a quantitative (18)F-FDG PET/CT metabolic parameter to assess the intensity of bone involvement in multiple myeloma Sci Rep 2019 9 1 16429 31712729 6848137 10.1038/s41598-019-52740-2
A. Paschali E. Panagiotidis T. Triantafyllou V. Palaska K. Tsirou E. Verrou et al. A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy Eur J Nucl Med Mol Imaging 2021 48 5 1487 1497 1:CAS:528:DC%2BB3cXit1Wmsb3F 33099659 10.1007/s00259-020-05078-1
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.